XLO vs. MOLN, CRDF, ACOG, ZURA, FBRX, MEIP, IVVD, HURA, CGEN, and GNLX
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Molecular Partners (MOLN), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), Zura Bio (ZURA), Forte Biosciences (FBRX), MEI Pharma (MEIP), Invivyd (IVVD), TuHURA Biosciences (HURA), Compugen (CGEN), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.
Xilio Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 294.74%. Molecular Partners has a consensus target price of $8.00, suggesting a potential upside of 112.26%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Molecular Partners.
Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Molecular Partners has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Molecular Partners' return on equity of -50.66% beat Xilio Therapeutics' return on equity.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 6.3% of Xilio Therapeutics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Molecular Partners had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Xilio Therapeutics. Molecular Partners' average media sentiment score of 0.95 beat Xilio Therapeutics' score of 0.48 indicating that Molecular Partners is being referred to more favorably in the news media.
Xilio Therapeutics has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Xilio Therapeutics beats Molecular Partners on 9 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 9/16/2025 by MarketBeat.com Staff
Free XLO Stock Alerts